Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 2, 2009, Pages 717-723

  Murnane, K S ^a   Murai, N ^a   Howell, L L ^a,b,c   Fantegrossi, William E ^a,c  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DIMETHOXY (N) PROPYLTHIOPHENETHYLAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; COCAINE; DOPAMINE; N,N DIPROPYLTRYPTAMINE; NORADRENALIN; PSYCHEDELIC AGENT; PSYCHOSTIMULANT AGENT; SEROTONIN 2A AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG POTENCY; DRUG SUBSTITUTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEREOISOMERISM;

AMPHETAMINES; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; CONDITIONING, OPERANT; DISCRIMINATION (PSYCHOLOGY); DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; MALE; MICE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PHENETHYLAMINES; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM; TRYPTAMINES;

EID: 70350452574     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.156174     Document Type: Article

References (31)

1. Acquas E, Pisanu A, Spiga S, Plumitallo A, Zernig G, and Di Chiara G (2007) Differential effects of intravenous R,S-(+/-)-3,4- methylenedioxymethamphetamine (MDMA, Ecstasy) and its S(+)- and R(-)-enantiomers on dopamine transmission and extracellular signal regulated kinase phosphorylation (pERK) in the rat nucleus accumbens shell and core. J Neurochem 102:121-132. (Pubitemid 46906254)
2. Baker LE, Broadbent J, Michael EK, Matthews PK, Metosh CA, Saunders RB, West WB, and Appel JB (1995) Assessment of the discriminative stimulus effects of the optical isomers of ecstasy (3,4-methylenedioxymethamphetamine; MDMA). Behav Pharmacol 6:263-275.
3. Blough B, Landavazo T, Partilla JS, Page KM, and Rothman BB (2007) The biogenic amine transporter properties of selected Shulgin tryptamines. College on Problems of Drug Dependence; Abstract 50; 2007 June; Quebec City, Quebec, Canada.
4. Bondareva T, Wesolowska A, Dukat M, Lee M, Young R, and Glennon RA (2005) S(+) and R(-)N-methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) as discriminative stimuli:
5. Brauer LH, Goudie AJ, and de Wit H (1997) Dopamine ligands and the stimulus effects of amphetamine: animal models versus human laboratory data. Psychopharmacology 130:2-13.
6. Colpaert FC, Niemegeers CJ, and Janssen PA (1980) Factors regulating drug cue sensitivity: the effect of training dose in fentanyl-saline discrimination. Neuropharmacology 19:705-713.
7. Davids E, Zhang K, Kula NS, Tarazi FI, and Baldessarini RJ (2002) Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats. J Pharmacol Exp Ther 301:1097-1102. (Pubitemid 34595102)
8. Easton N and Marsden CA (2006) Ecstasy: are animal data consistent between species and can they translate to humans? J Psychopharmacol 20:194-210.
9. Fantegrossi WE, Godlewski T, Karabenick RL, Stephens JM, Ullrich T, Rice KC, and Woods JH (2003) Pharmacological characterization of the effects of 3,4- methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl) 166:202-211. (Pubitemid 36384765)
10. Fantegrossi WE, Kiessel CL, De la Garza R 2nd, and Woods JH (2005a) Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. Psychopharmacology (Berl) 181:529-536.
11. Fantegrossi WE, Harrington AW, Eckler JR, Arshad S, Rabin RA, Winter JC, Coop A, Rice KC, and Woods JH (2005b) Hallucinogen-like actions of 2,5-dimethoxy-4- (n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology (Berl) 181:496-503. (Pubitemid 41480898)
12. Fantegrossi WE, Murnane KS, and Reissig CJ (2008) The behavioral pharmacology of hallucinogens. Biochem Pharmacol 75:17-33.
13. Fantegrossi WE, Murai N, Mathúna BO, Pizarro N, and de la Torre R (2009) Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations. J Pharmacol Exp Ther 329:1006-1015.
14. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, and Hanson GR (2007) New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47:681-698. (Pubitemid 46272143)
15. Glennon RA, Yousif M, and Patrick G (1988) Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs. Pharmacol Biochem Behav 29:443-449. (Pubitemid 19256799)
16. Green AR, Mechan AO, Elliott JM, O'Shea E, and Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55:463-508. (Pubitemid 37013213)
17. Kuhar MJ, McGirr KM, Hunter RG, Lambert PD, Garrett BE, and Carroll FI (1999) Studies of selected phenyltropanes at monoamine transporters. Drug Alcohol Depend 56:9-15.
18. Liechti ME, Baumann C, Gamma A, and Vollenweider FX (2000a) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22:513-521. (Pubitemid 30145619)
19. Liechti ME, Saur MR, Gamma A, Hell D, and Vollenweider FX (2000b) Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 23:396-404.
20. Logan BJ, Laverty R, Sanderson WD, and Yee YB (1988) Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity. Eur J Pharmacol 152:227-234. (Pubitemid 18199600)
21. Lyon RA, Glennon RA, and Titeler M (1986) 3,4- Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology (Berl) 88:525-526.
22. Murnane KS, Fantegrossi WE, Godfrey J, Neidert L, and Howell LL (2009) Endocrine and neurochemical effects of S(+) and R(-)-MDMA in rhesus macaques. 2009 Experimental Biology Meeting; Abstract 589.11. 2008 Apr 5-9; San Diego, CA.
23. Nagai F, Nonaka R, and Satoh Hisashi Kamimura K (2007) The effects of nonmedically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559:132-137. (Pubitemid 46295399)
24. Nash JF, Roth BL, Brodkin JD, Nichols DE, and Gudelsky GA (1994) Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors. Neurosci Lett 177:111-115. (Pubitemid 124016510)
25. O'Shea E, Esteban B, Camarero J, Green AR, and Colado MI (2001) Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology 40:65-74. (Pubitemid 33779801)
26. Schuster C and Johanson C (1988) Relationship between the discriminative stimulus properties and subjective effects of drugs, in Transduction Mechanisms of Drug Stimuli (Colpaert F and Balster R, eds) pp 161-175, Springer, Berlin. (Pubitemid 18040696)
27. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, and Roth BL (2003) 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63:1223-1229. (Pubitemid 36627216)
28. Stone DM, Hanson GR, and Gibb JW (1987) Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology 26:1657-1661. (Pubitemid 18008368)
29. Vollenweider FX, Gamma A, Liechti M, and Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMAnaïve healthy volunteers. Neuropsychopharmacology 19:241-251. (Pubitemid 28491334)
30. Winter JC, Fiorella DJ, Timineri DM, Filipink RA, Helsley SE, and Rabin RA (1999) Serotonergic receptor subtypes and hallucinogen-induced stimulus control. Pharmacol Biochem Behav 64:283-293.
31. Yarosh HL, Katz EB, Coop A, and Fantegrossi WE (2007) MDMA-like behavioral effects of N-substituted piperazines in the mouse. Pharmacol Biochem Behav 88:18-27. (Pubitemid 47381540)